Bisphosphonate-related osteonecrosis of the jaw: Tip of the iceberg

Journal of Craniofacial Surgery

Volumn 21, Issue 1, 2010, Pages 25-32

  Knight, Robert John W ^a   Reddy, Chaithan ^a   Rtshiladze, Michael A ^a   Lvoff, Gregory ^a   Sherring, David ^a   Marucci, Damian ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Bisphosphonate; Osteonecrosis; Prophylaxis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; HEALTH; HUMAN; INCIDENCE; JAW DISEASE; PATHOPHYSIOLOGY; RISK FACTOR;

AGED; BONE DENSITY CONSERVATION AGENTS; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HUMANS; INCIDENCE; JAW DISEASES; OSTEONECROSIS; RISK FACTORS; WORLD HEALTH;

EID: 77649228269     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/SCS.0b013e3181c347a0     Document Type: Article

References (51)

1. Hellstein JW, Marek CL. Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg 2004;62:1563-1566
2. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376
3. Pogrel MA, Miller CE. A case of maxillary necrosis. J Oral Maxillofac Surg 2003;61:489-493
4. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-514
5. Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA 2006;295:2833-2836
6. Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34:613-617
7. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65:1328-1331
8. Zavras A, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg. 2006;64:917-923
9. Durie BGM, Katz M, Crowley J, et al. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102
10. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-631
11. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423
12. Dodson TB, Raje NS, Caruso PA, et al. Case 9-2008Va 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med 2008;358: 1283-1291
13. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356: 1809-1822
14. Compston J. Treatments for osteoporosisVlooking beyond the HORIZON. N Engl J Med 2007;356:1878-1880
15. Sanna G, Zampino M, Pelosi G, et al. Jaw avascular necrosis associated with long-term use of bisphosphonates. Annal Oncol 2005;16: 1207-1213
16. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93
17. Lenz J-H, Steiner-Krammer B, SchmidtW, et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005;33:395-403
18. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007;65:573-580
19. Graziani F, Cei S, La Ferla F, et al. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy. J Craniofac Surg 2006;17:876-879
20. Sheridan C. Can Fdouble blockbuster- strengthen Amgen's backbone? Nat Biotechnol 2008;26:260-262
21. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-1084
22. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-2897
23. Shenker NG, Jawad ASM. Bisphosphonates and osteonecrosis of the jaw. Rheumatology 2007;46:1049-1051
24. Assael LA. A time for perspective on bisphosphonates. J Oral Maxillofac Surg 2006;64:877-879
25. Agrillo A, Petrucci M, Tedaldi M, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg 2006;17:1080-1082
26. Bouquot JE, McMahon RE, Glueck CJ. Bone marrow edema: mild or nascent variant of ischemic bone disease. J Oral Maxillofac Surg 2007;66:205-208
27. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36:319-328
28. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-285
29. Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-307
30. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41:318-320
31. Sedghizadeh PP, Kumar SKS, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008;66:767-775
32. Senel FC, Tekin US, Durmus A, et al. Severe osteomyelitis of the mandible associated with the use of nonYnitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 2007;65:562-565
33. McMahon RE, Bouquot JE, Glueck CJ, et al. Osteonecrosis: a multifactorial etiology. J Oral Maxillofac Surg 2004;62:94-95
34. Hooper SJ, Crean SJ, Lewis MAO, et al. Viable bacteria present within oral squamous cell carcinoma tissue. J Clin Microbiol 2006;44: 1719-1725
35. Kinjo T, Kamiyama K, Chinen K, et al. Squamous metaplasia induced by transfection of human papillomavirus DNA into cultured adenocarcinoma cells. Mol Pathol 2003;56:97-108
36. Mena S, Ortega A, Estrela JM. Oxidative stress in environmental-induced carcinogenesis. Mutat Res 2008;674:36-44
37. Abu-Id MH, Warnke PH, Gottschalk J, et al. BBis-phossy jaws[high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008;36:95-103
38. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006;21:1503-1505
39. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007;19: 315-322
40. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575
41. Vescovi P, Merigo E, Meleti M, et al. Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2008;66:831-833
42. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-1327
43. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144:2008-2015
44. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472
45. Body J-J, Coleman R, Clezardin P, et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. European Journal of Cancer 2007;43:852-858
46. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65: 2397-2410
47. Lacy MQ, Dispenzieri AQ, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-1053
48. Curi MM, dos Santos MO, Feher O, et al. Management of extensive osteoradionecrosis of the mandible with radical resection and immediate microvascular reconstruction. J Oral Maxillofac Surg 2007;65:434-438
49. Engroff SL, Kim DD. Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg 2007;65:2374-2385
50. Longobardi G, Boniello R, Gasparini G, et al. Surgical therapy for osteonecrotic lesions of the jaws in patients in therapy with bisphosphonates. J Craniofac Surg 2007;18: 1012-1017
51. Kademani D, Koka S, Lacy MQ, et al. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81:1100-1103